SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neptune Technologies & Bioressources Inc. - NTB.V
An SI Board Since July 2011
Posts SubjectMarks Bans Symbol
727 14 0 NEPT
Emcee:  Sultan Type:  Unmoderated
Neptune Wellness Solutions researches, develops and commercializes proprietary bioactive
ingredients and products with the goal of superior added-value and clinically proven health benefits. The
Company extracts a range of bioactive ingredients such as novel proprietary omega-3 phospholipids from
abundant yet underexploited marine biomass including Krill, a cold deep water zooplankton. Neptune’s
first commercially available product is Neptune Krill Oil (NKO®), which represents marine based omega-3
phospholipids with potential in cardiovascular, cognitive and anti-inflammatory disorders. Neptune is pursuing
market opportunities in the nutraceutical market including dietary supplements and functional foods. The
Company is also pursuing opportunities in the pharmaceutical market through its pharmaceutical subsidiaries,Acasti and NeuroBioPharm (including medical food, over-the-counter and prescription drug applications).

neptunecorp.com

NOTE: Neptune trades on Toronto.. For Canadian & US quote, enter NEPT

Acasti Pharma Inc. is 35% owned by Neptune.. For Canadian & US quote, enter ACST

acastipharma.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
727CEO Letter to Investors neptunecorp.comSultan-February 13
726Neptune to Report Fiscal 2020 Third Quarter Financial Results on February 13, 20Sultan-February 13
725Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPreSultan-February 10
724Is Neptune Wellness Solutions Inc (TSE:NEPT)(NASDAQ:NEPT) A Good Bet Right Now? Sultan-January 28
723[tweet]Sultan-January 20
722Neptune is gearing up for launching forestremedies.comSultan-January 17
721Neptune Provides Corporate Updates and Discusses 2020 Initiatives finance.yahooSultan-January 10
720Chen is a long time Bull on ACST and has 'not a bad record' on some biotSultan112/30/2019
719bnnbloomberg.caSultan-12/28/2019
718Acasti bull calls pullback 'unwarranted' Dec. 24, 2019 8:53 AM ET|About:E_K_S-12/24/2019
717Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3Sultan112/24/2019
716FDA approves use of drug to reduce risk of cardiovascular events in certain adulSultan112/14/2019
715This is what ACST is working on and it's the exact same basic drug (icosapenSultan112/13/2019
714This is what ACST is working on and it's the exact same basic drug (icosapenE_K_S-12/13/2019
713AMRN news .. Let's see what ACST delivers next week.. The U.S. Food and DrSultan112/13/2019
712NEPT has been showing support at 2.46 and resistance at 3.16. Bullish indicationAlejandroo Green-12/11/2019
711[tweet]Sultan-12/2/2019
710The perfect omega-3 torontosun.comSultan-12/2/2019
709Acsti COO Interview youtube.comSultan-11/27/2019
708Neptune Announces an Amended and Restated Agreement with Canopy finance.yahoo.cSultan-11/20/2019
707Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPrSultan-11/18/2019
706Neptune CEO: CBD partnership with IFF has given the company 'extra edge'Sultan-11/15/2019
705Acasti Pharma Inc. (ACST) CEO Jan D'Alvise on Q2 2020 Results - Earnings CalSultan-11/14/2019
704Neptune Reports Fiscal 2020 Second Quarter Results finance.yahoo.comSultan-11/12/2019
703Neptune Wellness Solutions Inc. 2020 Q2 - Results - Earnings Call Presentation Sultan-11/11/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):